A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old (MYAMERGE)
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis
In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells.
In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase).
In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again.
The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine.
The main question researchers want to answer is:
- Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies?
Researchers will also learn more about:
- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
- How the body processes felzartamab
- How felzartamab affects the participants' disease severity
- How many participants' bodies make antibodies against felzartamab after treatment
This study will be done as follows:
-
Participants will join the study after signing an informed consent form, also known as an ICF.
-
Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have.
- If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
- If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking.
-
Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein.
-
During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives.
-
After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The primary objective of this study is to evaluate the efficacy of felzartamab in participants with gMG compared with placebo. The secondary objectives of this study are to evaluate the efficacy, safety, pharmacokinetics (PK) of felzartamab and anti-drug antibodies (ADAs) in participants with gMG.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:US Biogen Clinical Trial Center
- 電話番号:866-633-4636
- メール:clinicaltrials@biogen.com
研究連絡先のバックアップ
- 名前:Global Biogen Clinical Trial Center
- メール:clinicaltrials@biogen.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Documented diagnosis of gMG.
- Myasthenia Gravis Foundation of America (MGFA) clinical Classification II to IVa at Screening and Randomization.
- Corticosteroids must be administered orally on a daily or alternate-day schedule; pulse corticosteroid therapy is not permitted. Concomitant treatment with permitted acetylcholinesterase inhibitor (AChEIs) and/or allowed conventional immunosuppressant standard therapy (ISTs) is allowed, provided all therapies meet protocol-defined requirements.
- Participants receiving AChEIs must have been on a stable dose prior to Randomization.
- Participants receiving Azathioprine must be on treatment and a stable dose prior to Randomization.
- Participants receiving other conventional immunosuppressive drugs (e.g., mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, tacrolimus), or other Sponsor-approved therapy) must be on treatment and on a stable dose prior to Randomization.
- Participants should be up to date on all vaccinations in accordance with local country or regional public health authority guidelines, where feasible. Required vaccinations should be completed at least 4 weeks prior to screening, where applicable. A screening period extension may be permitted to allow completion of required vaccinations.
Key Exclusion Criteria:
- MGFA Class I or IVb, or V at Screening.
- History of myasthenic crisis requiring hospitalization, mechanical ventilation, or intensive care unit admission prior to Screening.
- Anticipated need for rescue therapy between Screening and Randomization.
- Congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, or any other neuromuscular disorder that could confound the evaluation of gMG.
- Thymectomy for benign thymoma within 12 months prior to Randomization or planned thymectomy during the study.
- Unresected, active or recurrent thymoma.
- History of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, or other malignancies considered cured with minimal risk of recurrence, as determined by the Investigator.
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Cohort 1: Felzartamab or Placebo
Participants will receive multiple intravenous (IV) doses of felzartamab or placebo. |
Administered IV Administered IV
他の名前:
|
|
実験的:Cohort 2: Felzartamab
Participants will receive multiple IV doses of felzartamab. |
Administered IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
時間枠:Baseline, Week 26
|
Baseline, Week 26
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Cohort 1: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
時間枠:Baseline, Week 26
|
Baseline, Week 26
|
|
Cohorts 1 and 2: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESI)
時間枠:From first dose of study drug up to end of study follow-up (Up to Week 52)
|
From first dose of study drug up to end of study follow-up (Up to Week 52)
|
|
Cohorts 1 and 2: Felzartamab Serum Concentrations Over Time
時間枠:Predose and at multiple timepoints postdose up to Week 44
|
Predose and at multiple timepoints postdose up to Week 44
|
|
Cohorts 1and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
時間枠:Baseline up to Week 52
|
Baseline up to Week 52
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Medical Director、Biogen
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 299MG201
- 2026-527803-94 (その他の識別子:EU CT Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。